HENDERSON, Nev.--(BUSINESS WIRE)--Feb. 21, 2019--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host
a conference call with management to discuss the fourth quarter and full
year 2018 financial results, provide an update on the company's
business, and discuss expectations for the future on Thursday, February
28, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Thursday, February 28, 2019 @ 4:30 p.m.
Eastern/1:30 p.m. Pacific
Domestic: (877) 837-3910, Conference ID# 2797623
(973) 796-5077, Conference ID# 2797623
For interested individuals unable to join the call, a replay will be
available from February 28, 2019 @ 7:30 p.m. ET/4:30 p.m.
PT through March 7, 2019 until 11:59 p.m. ET/8:59 p.m. PT.
Domestic Replay Dial-In #: (855) 859-2056, Conference ID# 2797623
Replay Dial-In #: (404) 537-3406, Conference ID# 2797623
This conference call will also be webcast. Listeners may access the
webcast, which will be available on the investor relations page
of Spectrum Pharmaceuticals' website: http://investor.sppirx.com/events-and-presentations
on February 28, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in hematology and oncology. Spectrum has an advanced
stage pipeline that has the potential to transform the company.
Spectrum's strong track record for in-licensing and acquiring
differentiated drugs, and expertise in clinical development have
generated a robust, diversified, and growing pipeline of product
candidates in advanced-stage Phase 2 and Phase 3 studies. More
information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.These
statements are based on management's current beliefs and expectations.These statements include, but are not limited to, statements that
relate to Spectrum’s business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, the timing and results of FDA decisions, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical
fact.Risks that could cause actual results to differ include the
possibility that Spectrum’s existing and new drug candidates may not
prove safe or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not receive
approval in a timely manner or at all, the possibility that our existing
and new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that our
efforts to acquire or in-license and develop additional drug candidates
may fail, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks that are
described in further detail in the company's reports filed with the
Securities and Exchange Commission.The company does not plan to
update any such forward-looking statements and expressly disclaims any
duty to update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a
registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc.Any other
trademarks are the property of their respective owners.
© 2019 Spectrum Pharmaceuticals, Inc.All Rights Reserved
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005031/en/
Source: Spectrum Pharmaceuticals, Inc.
Vice President, Strategic
Planning & Investor Relations